Rachel Humphrey
Directeur/Membre du Conseil chez PYXIS ONCOLOGY, INC.
Fortune : 217 159 $ au 31/05/2024
Profil
Rachel W.
Humphrey is currently the President & Chief Executive Officer at Normunity, Inc. She is also an Independent Director at Pyxis Oncology, Inc., a Director at Asylia Therapeutics, Inc., and a Director at Sporos Bioventures, Inc. In her former positions, Dr. Humphrey served as an Independent Director at Xilio Therapeutics, Inc. from 2019 to 2022.
She was also the Director & Chief Medical Officer at Treadwell Therapeutics, Inc. in 2020.
From 2003 to 2012, she worked at Bristol Myers Squibb Co. as the Vice President-Product Development.
Additionally, she held the position of Head-Immuno Oncology at Eli Lilly & Co. in 2015 and served as the Chief Medical Officer & Executive Vice President at Mirati Therapeutics, Inc. from 2012 to 2013.
Dr. Humphrey was the Senior Vice President at CytomX Therapeutics Holdings LLC and the Senior Vice President & Head-Immuno Oncology at AstraZeneca LP from 2013 to 2014.
From 2015 to 2019, she worked as the Chief Medical Officer & Senior Vice President at CytomX Therapeutics, Inc. She also served as the Chief Medical Officer at Black Diamond Therapeutics, Inc. in 2020 and as the Head-Research & Development at Tio Bioventures in the same year.
Dr. Humphrey has also been a Scientific Advisor at eFFECTOR Therapeutics, Inc.Dr. Humphrey completed her undergraduate studies at Harvard University and holds a doctorate degree from Case Western Reserve University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
PYXIS ONCOLOGY, INC.
0,10% | 18/04/2024 | 58 064 ( 0,10% ) | 217 159 $ | 31/05/2024 |
Postes actifs de Rachel Humphrey
| Sociétés | Poste | Début |
|---|---|---|
| PYXIS ONCOLOGY, INC. | Directeur/Membre du Conseil | 11/08/2022 |
Normunity, Inc.
 Normunity, Inc. Miscellaneous Commercial ServicesCommercial Services Normunity, Inc. is a biotechnology company that creates precision immuno-oncology medicines called immune normalizers. The company is based in West Haven, CT and has subsidiaries in the United States. These medicines target novel mechanisms that free the body's normal immunity against cancer. Normunity is based on an ongoing academic-biotech partnership with the lab of Dr. Lieping Chen at Yale School of Medicine. The company is advancing an emerging pipeline of immune normalizers, including initial drug programs that target mechanisms that drive the exclusion of T-cells from immune-sensitive tumors and other mechanisms that are barriers to normal immune function in cancer. The CEO of the company is Rachel W. Humphrey. | Directeur Général | - |
Sporos Bioventures, Inc.
 Sporos Bioventures, Inc. Medical/Nursing ServicesHealth Services Sporos Bioventures, Inc. is a private biopharmaceutical company based in Houston, TX. Sporos Bioventures, Inc. aims to transform the drug development process by identifying novel disease mechanisms and strategically deploying talent, capital, and access to operational resources to catalyze the development of breakthrough medicines. Sporos' current pipeline is diversified across three business units and includes multiple clinical-stage candidates that are being investigated for the treatment of multiple indications in cancer and immune disease. The company provides centralized expertise, resources, and core infrastructure so that the portfolio companies can focus primarily on their research development programs. The company was founded by Peter Feinberg, Ronald A. DePinho, Jeno Gyuris, Joseph Kekst, Harold Levy, Alex M. Cranberg, Louis Feinberg, Michael S. Wyzga, Dana Levy, and the CEO is Stephen Rubino. | Directeur/Membre du Conseil | 04/01/2022 |
Asylia Therapeutics, Inc.
 Asylia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Asylia Therapeutics, Inc. is a private biotechnology company founded in 2019 by Richard Jones, Robert Z. Orlowski, and Ronald A. DePinho. The company is based in Houston, TX. Asylia Therapeutics is focused on developing novel immune modulating therapies for cancer and autoimmune diseases. The company's drug pipeline is capable of modulating antigen presentation to the immune system, which has produced anti-tumor responses across multiple cancer models. The company is supported by a $3 million grant from the Cancer Prevention & Research Institute of Texas. The CEO is Karthik Radhakrishnan. | Directeur/Membre du Conseil | - |
Anciens postes connus de Rachel Humphrey
| Sociétés | Poste | Fin |
|---|---|---|
| XILIO THERAPEUTICS, INC. | Directeur/Membre du Conseil | 03/02/2022 |
| BLACK DIAMOND THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 04/08/2021 |
Tio Bioventures
 Tio Bioventures Investment ManagersFinance Tio Bioventures (Tio Bioventures) is a venture capital firm founded in 2019 by Tak Wah Mak and Shane Burgess. The firm is headquartered in New York. | Directeur Technique/Scientifique/R&D | 01/05/2020 |
Treadwell Therapeutics, Inc.
 Treadwell Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Treadwell Therapeutics, Inc. operates as a clinical-stage oncology firm. It develops small molecules designed to leverage world-class, innovative science in cancer biology and immune-oncology with pan-cancer potential, including hematological malignancies from the TIO Discovery development engine. The company was founded by Tak Wah Mak and Mark R. Bray in July 2019 and is headquartered in New York, NY. | Directeur Technique/Scientifique/R&D | 01/05/2020 |
| CYTOMX THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 19/08/2019 |
Formation de Rachel Humphrey
| Harvard University | Undergraduate Degree |
| Case Western Reserve University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 7 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| ELI LILLY AND COMPANY | Health Technology |
| CYTOMX THERAPEUTICS, INC. | Health Technology |
| XILIO THERAPEUTICS, INC. | Health Technology |
| BLACK DIAMOND THERAPEUTICS, INC. | Health Technology |
| PYXIS ONCOLOGY, INC. | Health Technology |
| EFFECTOR THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 8 |
|---|---|
Mirati Therapeutics, Inc.
 Mirati Therapeutics, Inc. BiotechnologyHealth Technology Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA. | Health Technology |
CytomX Therapeutics Holdings LLC
 CytomX Therapeutics Holdings LLC Pharmaceuticals: MajorHealth Technology CytomX Therapeutics Holdings LLC engaged in the development of new generation targeted antibody therapeutics. The company was founded by Frederick W. Gluck on January 31, 2008 and is headquartered in Santa Barbara, CA. | Health Technology |
AstraZeneca LP
 AstraZeneca LP Pharmaceuticals: MajorHealth Technology Part of AstraZeneca PLC, AstraZeneca LP is a pharmaceutical company that focuses on developing and commercializing prescription drugs for various therapeutic areas. The company is based in Wilmington, DE. | Health Technology |
Treadwell Therapeutics, Inc.
Treadwell Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Treadwell Therapeutics, Inc. operates as a clinical-stage oncology firm. It develops small molecules designed to leverage world-class, innovative science in cancer biology and immune-oncology with pan-cancer potential, including hematological malignancies from the TIO Discovery development engine. The company was founded by Tak Wah Mak and Mark R. Bray in July 2019 and is headquartered in New York, NY. | Health Technology |
Tio Bioventures
Tio Bioventures Investment ManagersFinance Tio Bioventures (Tio Bioventures) is a venture capital firm founded in 2019 by Tak Wah Mak and Shane Burgess. The firm is headquartered in New York. | Finance |
Asylia Therapeutics, Inc.
Asylia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Asylia Therapeutics, Inc. is a private biotechnology company founded in 2019 by Richard Jones, Robert Z. Orlowski, and Ronald A. DePinho. The company is based in Houston, TX. Asylia Therapeutics is focused on developing novel immune modulating therapies for cancer and autoimmune diseases. The company's drug pipeline is capable of modulating antigen presentation to the immune system, which has produced anti-tumor responses across multiple cancer models. The company is supported by a $3 million grant from the Cancer Prevention & Research Institute of Texas. The CEO is Karthik Radhakrishnan. | Health Technology |
Sporos Bioventures, Inc.
Sporos Bioventures, Inc. Medical/Nursing ServicesHealth Services Sporos Bioventures, Inc. is a private biopharmaceutical company based in Houston, TX. Sporos Bioventures, Inc. aims to transform the drug development process by identifying novel disease mechanisms and strategically deploying talent, capital, and access to operational resources to catalyze the development of breakthrough medicines. Sporos' current pipeline is diversified across three business units and includes multiple clinical-stage candidates that are being investigated for the treatment of multiple indications in cancer and immune disease. The company provides centralized expertise, resources, and core infrastructure so that the portfolio companies can focus primarily on their research development programs. The company was founded by Peter Feinberg, Ronald A. DePinho, Jeno Gyuris, Joseph Kekst, Harold Levy, Alex M. Cranberg, Louis Feinberg, Michael S. Wyzga, Dana Levy, and the CEO is Stephen Rubino. | Health Services |
Normunity, Inc.
Normunity, Inc. Miscellaneous Commercial ServicesCommercial Services Normunity, Inc. is a biotechnology company that creates precision immuno-oncology medicines called immune normalizers. The company is based in West Haven, CT and has subsidiaries in the United States. These medicines target novel mechanisms that free the body's normal immunity against cancer. Normunity is based on an ongoing academic-biotech partnership with the lab of Dr. Lieping Chen at Yale School of Medicine. The company is advancing an emerging pipeline of immune normalizers, including initial drug programs that target mechanisms that drive the exclusion of T-cells from immune-sensitive tumors and other mechanisms that are barriers to normal immune function in cancer. The CEO of the company is Rachel W. Humphrey. | Commercial Services |
